What is the current HIV Vaccine market size?

The HIV Vaccine market size is approximately USD 1.2 billion as of 2023.

What is the future outlook for the HIV Vaccine market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the HIV Vaccine market?

Increasing awareness and government initiatives are driving the HIV Vaccine market growth.

What are the major challenges facing the HIV Vaccine market?

High development costs and limited access to healthcare are challenging the HIV Vaccine market.

Which regions are leading the HIV Vaccine market?

North America and Europe are leading the HIV Vaccine market due to high awareness.

Who are the top companies in the HIV Vaccine market?

Top companies include GlaxoSmithKline and Sanofi, driving innovation and growth.

What future opportunities exist in the HIV Vaccine market?

Emerging markets and new technologies offer significant future opportunities for growth.

How is technology impacting the HIV Vaccine market?

Advances in vaccine technology are improving efficacy and driving market growth.

What is the current regulatory landscape for the HIV Vaccine market?

Regulatory frameworks are supporting innovation and growth in the HIV Vaccine market.

How will the HIV Vaccine market evolve in the next 5 years?

The market will be shaped by emerging technologies and increasing global access.

HIV Vaccine Market Metrics & Forecast Analysis 2033

HIV Vaccine by Type (Self-assembling Nanoparticle HIV Vaccine, mRNA AIDS Vaccine, Others), by Application (Research Institutions, Medical Company), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 82

Forecast Period: 2026 - 2033

Market Size: $850 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 82

Forecast Period: 2026 - 2033

Market Size: $850 million

CAGR: 10.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

HIV Vaccine Market Overview

The HIV Vaccine market refers to the global industry focused on developing and distributing vaccines to prevent and treat Human Immunodeficiency Virus (HIV) infections. As the HIV Vaccine market size is expected to reach $1.8 billion by 2026, the growth outlook and market forecast indicate a promising industry expansion driven by advancements in vaccine technology and increasing investments in research and development. The scope of this market encompasses various vaccine types, including preventive and therapeutic vaccines, and their applications across different regions and patient populations.

Loading chart…

The current HIV Vaccine market size is approximately $1.2 billion, with a growth forecast indicating a compound annual growth rate (CAGR) of 8.5% during the forecast period from 2026 to 2033. Key forces shaping the industry include technology shifts towards novel vaccine platforms, regulations supporting vaccine development and distribution, and consumer behavior driven by increasing awareness about HIV prevention and treatment. The largest region in the HIV Vaccine market is North America, while the fastest-growing region is Asia-Pacific, driven by expanding healthcare infrastructure and growing investments in vaccine research and development.

Report Overview

Report Attribute	Details
Market size value in 2025	850.00 million
Revenue forecast in 2033	1.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Uvax Bio; Johnson & Johnson; Sanofi; GSK
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The HIV Vaccine market is poised for significant growth, driven by increasing demand for effective prevention and treatment options. Understanding the dynamics of this market is crucial for stakeholders to navigate its complexities and capitalize on emerging opportunities.

Growth Drivers2 items

Advances in vaccine technology are enhancing the efficacy and safety of HIV vaccines, contributing to the growth of the HIV Vaccine market size. This has led to a significant increase in investments in research and development, further fueling market expansion.

Government initiatives and public-private partnerships are playing a crucial role in promoting awareness, funding research, and ensuring access to HIV vaccines, thereby driving the growth forecast of the HIV Vaccine market.

Restraints2 items

High development costs and the lengthy regulatory approval process for new HIV vaccines are significant restraints on the market, potentially limiting the HIV Vaccine market size and growth forecast.

Supply chain complexities and the need for sophisticated distribution networks to maintain vaccine potency are also hindering the growth of the HIV Vaccine market, making it challenging for manufacturers to ensure widespread availability.

Opportunities2 items

The emerging markets in low- and middle-income countries present significant opportunities for the HIV Vaccine market, as these regions have the highest burden of HIV infections and limited access to preventive measures, thus driving the need for vaccines.

The integration of HIV vaccines with other preventative measures, such as pre-exposure prophylaxis (PrEP), offers a comprehensive approach to HIV prevention, opening up new avenues for market growth and expansion.

Challenges2 items

Ensuring vaccine affordability and accessibility, especially in resource-poor settings, remains a significant challenge for the HIV Vaccine market, necessitating innovative pricing strategies and distribution models.

Addressing vaccine hesitancy and misinformation through effective communication and education campaigns is crucial to the success of HIV vaccine programs and the overall growth of the HIV Vaccine market size.

Market Segmentation

Loading chart…

The HIV Vaccine market can be segmented based on Type, which includes various subtypes such as preventive and therapeutic vaccines. The preventive vaccines are designed to prevent HIV infection, while therapeutic vaccines are used to treat individuals already infected with HIV. Understanding the HIV Vaccine segmentation by type is crucial to determine the market size and growth prospects.

The Application segment of the HIV Vaccine market includes subtypes such as pre-exposure prophylaxis, post-exposure prophylaxis, and treatment. Pre-exposure prophylaxis involves the use of vaccines to prevent HIV infection in individuals who are at high risk, while post-exposure prophylaxis involves the use of vaccines to prevent HIV infection after exposure to the virus. The treatment application involves the use of vaccines to manage HIV infection in individuals already infected.

HIV Vaccine Segmentation Breakdown7 items

Type

Self-assembling Nanoparticle HIV Vaccine

mRNA AIDS Vaccine

Others

Application

Research Institutions

Medical Company

Regional Insights

Loading chart…

The HIV Vaccine market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of preventive measures, government policies, and investments in healthcare infrastructure.

Key drivers for each region include: North America - high awareness and ecosystem maturity, Europe - strong regulatory framework and research initiatives, Asia Pacific - large demographics and growing infrastructure, Latin America - increasing government support and public-private partnerships, and Middle East & Africa - rising demand for preventive measures and expanding healthcare systems.

The regional forecast indicates that Asia Pacific will experience significant growth, driven by factors such as increasing urbanization, education, and economic growth. In contrast, Middle East & Africa will face challenges due to limited access to healthcare and funding constraints. Understanding these regional dynamics is crucial for stakeholders to navigate the HIV Vaccine market effectively.

Competitive Landscape

The HIV Vaccine market is moderately consolidated, with a mix of global players and local companies competing on factors such as pricing, distribution, product innovation, certifications, and regulatory approvals. The HIV Vaccine competitive landscape is characterized by high competition, with companies focusing on key competitive levers to gain market share. Global players are driving the market, but local companies are also playing a significant role, particularly in emerging markets.

Companies in the HIV Vaccine market are adopting various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. To stay competitive, companies are focusing on technology, service model, channel strength, customization, and cost advantages. The following companies are implementing different strategies to stay ahead in the market:

Uvax Bio: regional expansion

Johnson & Johnson: innovation pipeline

Sanofi: premium pricing

GSK: local manufacturing

Uvax Bio: OEM tie-ups

GSK: vertical integration

Key HIV Vaccine Companies4 items

Uvax Bio

Johnson & Johnson

Sanofi

GSK

Market Ecosystem

The HIV Vaccine ecosystem comprises a complex network of stakeholders involved in the development, production, and distribution of HIV vaccines. It spans across upstream, midstream, and downstream segments, encompassing technology providers, suppliers, integrators, channels, and end users. The ecosystem's boundaries are defined by the interactions among these stakeholders, where value is created and captured through the exchange of goods, services, and knowledge.

Raw material suppliers — providing vaccine components

Technology providers — developing vaccine technologies

OEMs / manufacturers — producing HIV vaccines

Distributors / channel partners — delivering vaccines to healthcare systems

Service providers / after-sales — offering vaccine-related services

Regulators/standards bodies — overseeing vaccine safety and efficacy

End users / buyers — administering vaccines to patients

In the HIV Vaccine ecosystem, control points are largely influenced by regulators and standards bodies, who dictate the approval and adoption of vaccines. Dependency risks arise from input constraints, such as limited access to raw materials, and standards approvals, which can delay vaccine development. Switching costs and partnerships between stakeholders can also impact the ecosystem's dynamics. Furthermore, a thorough value chain analysis is necessary to understand the intricacies of the HIV Vaccine ecosystem, particularly in diverse regions where vaccine distribution and administration may vary.

Recent Industry Insights

The HIV Vaccine industry trends have witnessed significant developments over the last 12-18 months, driven by advancements in technology and shifting consumer needs. Recent partnerships, such as collaborations between pharmaceutical companies and research institutions, have accelerated the development of innovative vaccine candidates. Notable mergers and acquisitions have also taken place, enabling companies to expand their portfolios and enhance their research capabilities.

Furthermore, several product and technology launches have occurred, including the introduction of novel vaccine platforms and delivery systems. Regulatory changes, such as updated guidelines for vaccine approval, have also impacted the industry. Additionally, there has been a shift in consumer and enterprise trends, with a growing focus on preventative care and immunotherapy. Funding rounds and expansions have provided companies with the necessary resources to drive innovation and growth in the HIV Vaccine market.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the HIV Vaccine market. The HIV Vaccine market outlook is attractive, driven by increasing investments in research and development, government initiatives, and a growing demand for effective preventive measures. The competitive intensity is moderate, with several key players and new entrants in the market. The long-term outlook is promising, with a potential for significant growth due to the ongoing innovation landscape and unmet medical needs.

The demand-supply balance is expected to be stable, with a steady increase in demand and a corresponding rise in supply. However, key risk factors such as regulatory challenges, market access barriers, and clinical trial complexities may impact the market. Overall, the HIV Vaccine market offers opportunities for growth and investment, driven by its attractive market size and growing demand.

12 items

1. Executive Summary

2. HIV Vaccine Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global HIV Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global HIV Vaccine Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global HIV Vaccine Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global HIV Vaccine Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global HIV Vaccine Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global HIV Vaccine Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global HIV Vaccine Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global HIV Vaccine Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global HIV Vaccine Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global HIV Vaccine Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global HIV Vaccine Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global HIV Vaccine Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global HIV Vaccine Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global HIV Vaccine Market Competition by Key Manufacturers

9.1. Global HIV Vaccine Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global HIV Vaccine: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Uvax Bio

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Johnson & Johnson

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Sanofi

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. GSK

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global HIV Vaccine Market

Figure 4: Global HIV Vaccine Market: Drivers

Figure 5: Global HIV Vaccine Market: Challenges

Figure 6: Global HIV Vaccine Market: Trends

Figure 7: Global HIV Vaccine Market: Opportunity

Figure 8: Global HIV Vaccine Market: Restraint

Figure 9: Global HIV Vaccine Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global HIV Vaccine Market Value (USD Million) By Region

Figure 19: Global HIV Vaccine Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global HIV Vaccine Market Value (USD Million) By Region

Figure 27: Global HIV Vaccine Market Share (%) By: Regions (2032)

Figure 28: Global HIV Vaccine Market Volume (K) By Region

Figure 29: Global HIV Vaccine Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global HIV Vaccine Market Value (USD Million) By Region

Figure 37: Global HIV Vaccine Market Share (%) By: Regions (2032)

Figure 38: Global HIV Vaccine Market Volume (K) By Region

Figure 39: Global HIV Vaccine Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

103 items

Table 1: Market Segmentation Analysis

Table 2: Global HIV Vaccine Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global HIV Vaccine Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global HIV Vaccine Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global HIV Vaccine Market Value (USD Million) By Region

Table 14: Global HIV Vaccine Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global HIV Vaccine Market Volume (K) By Region

Table 31: Global HIV Vaccine Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global HIV Vaccine Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global HIV Vaccine Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global HIV Vaccine Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Uvax Bio Basic Information And Sales Area

Table 52: Uvax Bio. Products Portfolio

Table 53: Johnson & Johnson Basic Information And Sales Area

Table 54: Johnson & Johnson. Products Portfolio

Table 55: Sanofi Basic Information And Sales Area

Table 56: Sanofi. Products Portfolio

Table 57: GSK Basic Information And Sales Area

Table 58: GSK. Products Portfolio

Table 59: Global Market Value (USD Million) (2025-2032) By Type

Table 60: Global Market Share (%) By Type (2032)

Table 61: Global Market Value (USD Million) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Volume (K) (2025-2032) By Type

Table 64: Global Market Share (%) By Type (2032)

Table 65: Global Market Volume (K) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global HIV Vaccine Market Value (USD Million) By Region

Table 68: Global HIV Vaccine Market Share (%) By Region (2025-2032)

Table 69: North America Market Value (USD Million) (2025-2032) By Country

Table 70: North America Market Value (USD Million) (2025-2032) By Type

Table 71: North America Market Value (USD Million) (2025-2032) By Application

Table 72: Europe Market Value (USD Million) (2025-2032) By Country

Table 73: Europe Market Value (USD Million) (2025-2032) By Type

Table 74: Europe Market Value (USD Million) (2025-2032) By Application

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 78: South America Market Value (USD Million) (2025-2032) By Country

Table 79: South America Market Value (USD Million) (2025-2032) By Type

Table 80: South America Market Value (USD Million) (2025-2032) By Application

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 84: Global HIV Vaccine Market Volume (K) By Region

Table 85: Global HIV Vaccine Market Share (%) By Region (2025-2032)

Table 86: North America Market Volume (K) (2025-2032) By Country

Table 87: North America Market Volume (K) (2025-2032) By Type

Table 88: North America Market Volume (K) (2025-2032) By Application

Table 89: Europe Market Volume (K) (2025-2032) By Country

Table 90: Europe Market Volume (K) (2025-2032) By Type

Table 91: Europe Market Volume (K) (2025-2032) By Application

Table 92: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 93: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 95: South America Market Volume (K) (2025-2032) By Country

Table 96: South America Market Volume (K) (2025-2032) By Type

Table 97: South America Market Volume (K) (2025-2032) By Application

Table 98: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 99: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 101: Research Programs/Design For This Report

Table 102: Key Data Information From Secondary Sources

Table 103: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

HIV Vaccine Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	850.00 million
Revenue forecast in 2033	1.85 billion
Growth rate	CAGR of 10.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Uvax Bio; Johnson & Johnson; Sanofi; GSK
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

HIV Vaccine Segmentation Breakdown7 items

Type

Self-assembling Nanoparticle HIV Vaccine

mRNA AIDS Vaccine

Others

Application

Research Institutions

Medical Company

Regional Insights

Loading chart…

Competitive Landscape

Uvax Bio: regional expansion

Johnson & Johnson: innovation pipeline

Sanofi: premium pricing

GSK: local manufacturing

Uvax Bio: OEM tie-ups

GSK: vertical integration

Key HIV Vaccine Companies4 items

Uvax Bio

Johnson & Johnson

Sanofi

GSK

Market Ecosystem

Raw material suppliers — providing vaccine components

Technology providers — developing vaccine technologies

OEMs / manufacturers — producing HIV vaccines

Distributors / channel partners — delivering vaccines to healthcare systems

Service providers / after-sales — offering vaccine-related services

Regulators/standards bodies — overseeing vaccine safety and efficacy

End users / buyers — administering vaccines to patients

Recent Industry Insights

Analyst Overview

Table of Contents